MAPT and Alzheimer disease: Integrating quantitative immunohistochemistry, researchers have determined that the pathological expression of connective tissue growth factor and secreted protein acidic and cysteine rich (SPARC) impairs AD angiogenesis by counteracting the increased expression of proangiogenic factors, including Fgf2, Hif1a, and Angpt2, as pathological tissue Aβ and tau levels increase.